A phase II study of vismodegib, a hedgehog (Hh) pathway inhibitor, combined with gemcitabine and nab-paclitaxel (nab-P) in patients (pts) with untreated metastatic pancreatic ductal adenocarcinoma (PDA)

被引：30
|
作者：
De Jesus-Acosta, Ana
O'Dwyer, Peter J.
Ramanathan, Ramesh K.
Von Hoff, Daniel D.
Maitra, Anirban
Rasheed, Zeshaan
Zheng, Lei
Rajeshkumar, N. V.
Le, Dung T.
Hoering, Antje
Bolejack, Vanessa
Yabuuchi, Shinichi
Laheru, Daniel A.
机构：
[1] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA
[2] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
[3] Scottsdale HealthCare, Scottsdale, AZ USA
[4] Scottsdale Healthcare TGen, Virginia G Piper Canc Ctr Clin Trials, Scottsdale, AZ USA
[5] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[6] Johns Hopkins Univ, Baltimore, MD USA
[7] Canc Res & Biostat, Seattle, WA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 03期
关键词：
D O I：
10.1200/jco.2014.32.3_suppl.257
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
257
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Randomized phase 2 study of PEGPH20 Plus nab-paclitaxel/gemcitabine (PAG) vs AG in patients (Pts) with untreated, metastatic pancreatic ductal adenocarcinoma (mPDA)
    Hingorani, S. R.
    Bullock, A.
    Seery, T.
    Zheng, L.
    Sigal, D.
    Ritch, P. S.
    Braiteh, F. S.
    Zalupski, M.
    Bahary, N.
    Harris, W.
    Pu, J.
    Aldrich, C.
    Khelifa, S.
    Wu, W.
    Chondros, D.
    Jiang, P.
    Hendifar, A.
    ANNALS OF ONCOLOGY, 2017, 28
  • [32] Phase 1 trial of gemcitabine/nab-paclitaxel in combination with the autophagy inhibitor hydroxychloroquine in previously untreated patients with metastatic pancreatic adenocarcinoma.
    O'Hara, Mark H.
    Gallagher, Maryann
    Teitelbaum, Ursina R.
    Giantonio, Bruce J.
    Damjanov, Nevena
    Loaiza-Bonilla, Arturo
    Amaravadi, Ravi K.
    Heitjan, Daniel F.
    Vasilevskaya, Irina
    Von Hoff, Daniel D.
    Ramanathan, Ramesh K.
    Laheru, Dan
    De Jesus-Acosta, Ana
    Velculescu, Victor E.
    O'Dwyer, Peter J.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [33] Efficacy and safety of nab-paclitaxel plus S-1(nab-P/S-1) versus nab-paclitaxel plus gemcitabine (nab-P/Gem) for first-line chemotherapy in advanced pancreatic ductal adenocarcinoma (aPDAC): A randomized study
    Zong, Yuan
    Peng, Zhi
    Wang, Xicheng
    Shen, Lin
    Zhou, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [34] A randomized phase II trial of nab-paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer
    Hu, Zishuo Ian
    Bendell, Johanna C.
    Bullock, Andrea
    LoConte, Noelle K.
    Hatoum, Hassan
    Ritch, Paul
    Hool, Hugo
    Leach, Joseph W.
    Sanchez, James
    Sohal, Davendra P. S.
    Strickler, John
    Patel, Ravindranath
    Wang-Gillam, Andrea
    Firdaus, Irfan
    Yu, Kenneth H.
    Kapoun, Ann M.
    Holmgren, Eric
    Zhou, Lei
    Dupont, Jakob
    Picozzi, Vincent
    Sahai, Vaibhav
    O'Reilly, Eileen M.
    CANCER MEDICINE, 2019, 8 (11): : 5148 - 5157
  • [35] Multicenter phase I/II study of intravenous gemcitabine plus nab-paclitaxel combined with intraperitoneal paclitaxel for pancreatic ductal adenocarcinoma patients with peritoneal metastasis
    Yamada, Suguru
    Fujii, Tsutomu
    Yamamoto, Tomohisa
    Takami, Hideki
    Yoshioka, Isaku
    Yamaki, So
    Sonohara, Fuminori
    Shibuya, Kazuto
    Motoi, Fuyuhiko
    Hirano, Satoshi
    Murakami, Yoshiaki
    Inoue, Hitoshi
    Hayashi, Masamichi
    Kodera, Yasuhiro
    Sekimoto, Mitsugu
    Satoi, Sohei
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [36] Tumor burden reduction between primary and metastatic sites in advanced pancreatic cancer patients (pts) undergoing chemotherapy with nab-paclitaxel (Nab-P) and gemcitabine (Gem)
    Ventriglia, J.
    Laterza, M. M.
    Savastano, B.
    Petrillo, A.
    Tirino, G.
    Diana, A.
    Troiani, T.
    Ciardiello, F.
    De Vita, F.
    ANNALS OF ONCOLOGY, 2015, 26 : 101 - 102
  • [37] A study of relacorilant in combination with nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma.
    Borazanci, Erkut Hasan
    Bahary, Nathan
    Oberstein, Paul Eliezer
    Chung, Vincent
    Skeel, Roland T.
    Chiorean, E. Gabriela
    Greenstein, Andrew E.
    Pashova, Hristina I.
    Tudor, Iulia Cristina
    Mann, Grace
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [38] FOLFIRINOX or nab-paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: an observational study
    Servetto, Alberto
    Santaniello, Antonio
    Napolitano, Fabiana
    Foschini, Francesca
    Marciano, Roberta
    Cascetta, Priscilla
    Amato, Anna Rita
    Augurio, Maria Rosaria
    Maresca, Lucia
    De Placido, Pietro
    De Placido, Sabino
    Formisano, Luigi
    Bianco, Roberto
    FUTURE ONCOLOGY, 2022, 18 (21) : 2643 - 2654
  • [39] A pilot phase II multicenter study of nab-paclitaxel (Nab-P) and gemcitabine (G) as preoperative therapy for potentially resectable pancreatic cancer (PC)
    MacKenzie, Shawn
    Zeh, Herbert
    McCahill, Laurence E.
    Sielaff, Timothy D.
    Bahary, Nathan
    Gribbin, Thomas Edward
    Seng, John E.
    Leach, Joseph W.
    Harmon, Jocelyn
    Demeure, Michael J.
    Von Hoff, Daniel D.
    Moser, A. Jim
    Ramanathan, Ramesh K.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [40] Phase 1b study of WNT inhibitor vantictumab (VAN, human monoclonal antibody) with nab-paclitaxel (Nab-P) and gemcitabine (G) in patients (pts) with previously untreated stage IV pancreatic cancer (PC)
    Messersmith, W.
    Cohen, S.
    Shahda, S.
    Lenz, H-J.
    Weekes, C.
    Dotan, E.
    Denlinger, C.
    O'Neil, B.
    Kapoun, A.
    Zhang, C.
    Henner, R.
    Cattaruzza, F.
    Xu, L.
    Dupont, J.
    Brachmann, R.
    Uttamsingh, S.
    Farooki, A.
    Berlin, J.
    ANNALS OF ONCOLOGY, 2016, 27
12345